Advertisement

Tranexamic Acid Injection

[03 September 2014]

Products Affected - Description

Tranexamic acid injection, Fresenius Kabi (formerly APP)
100 mg/mL, 10 mL vial (63323-0563-10)

Reason for the Shortage

  • Fresenius Kabi (formerly APP) has tranexamic acid injection on shortage due to increased demand for the product.
  • X-Gen had tranexamic acid on shortage due to increased demand.

Available Products

Tranexamic acid injection, American Regent
100 mg/mL, 10 mL vial (00517-0960-10)
Tranexamic acid injection, Fresenius Kabi (formerly APP)
100 mg/mL, 10 mL ampule (63323-0563-97)
 
Tranexamic acid injection, Mylan Institutional
100 mg/mL, 10 mL vial (67457-0197-10)

Cyklokapron injection, Pfizer
100 mg/mL, 10 mL ampule (00013-1114-10)
 
Tranexamic acid injection, X-Gen
100 mg/mL, 10 mL vial (39822-1000-01)

Estimated Resupply Dates

Fresenius Kabi (formerly APP) has tranexamic acid 100 mg/mL 10 mL vials on back order and the company cannot estimate a release date.

Related Shortages

Updated

September 3, 2014; August 22, 2014; June 19, 2014; April 15, 2014; February 14, 2014; December 10, 2013; October 30, 2013; September 30, 2013; September 26, 2013; August 28, 2013; August 21, 2013; August 13, 2013; August 7, 2013, University of Utah, Drug Information Service. Copyright 2014, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement